Catatan bukti metode

Bioequivalence Analysis

Bioequivalence Analysis is a regulatory-grade statistical framework used to determine whether a test drug formulation (generic or reformulated) delivers the active ingredient to the systemic circulation at a rate and extent comparable to a reference product. Introduced by Donald J. Schuirmann in 1987, the method operationalizes equivalence through the Two One-Sided Tests (TOST) procedure, replacing the ambiguous absence-of-difference paradigm with an explicit equivalence margin evaluated on log-transformed pharmacokinetic endpoints such as AUC and C_max.

Sources recorded, not reviewed

Catatan sumber

Kutipan disalin apa adanya dari catatan sumber metode. Tidak ada verifikasi tingkat klaim yang disimpulkan darinya.

Bioequivalence Analysis (Two One-Sided Tests)

Catatan metode taksonomi · hypothesis-test / pharmacometrics

Schuirmann, D. J. (1987). A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. Journal of Pharmacokinetics and Biopharmaceutics, 15(6), 657–680. · DOI 10.1007/BF01068419

Buka metode lengkap

Klaim yang dikurasi

Klaim tersimpan dalam buku besar bukti, masing-masing dengan penilaiannya sendiri.

Belum ada klaim yang dikurasi

Tampilan ini tidak menciptakan penilaian klaim ketika buku besar tidak memilikinya.

Metode terkait

Dihasilkan dari grafik metode dan ditampilkan sebagai relasi yang disarankan mesin — tidak ada klaim bukti yang disimpulkan.

Same method familyEquivalence Test (TOST)machine-suggested · Relational suggestion, not evidence.Used in the same domainPharmacokinetic Compartment Modelmachine-suggested · Relational suggestion, not evidence.